N-(5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(5-fluoro-6-methylpyridin-2-yl)-1H-imidazol-2-yl)acetamide | 1132610-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: N-(5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(5-fluoro-6-methylpyridin-2-yl)-1H-imidazol-2-yl)acetamide
• 英文别名: N-[5-(5-fluoro-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-1H-imidazol-2-yl]acetamide
• CAS: 1132610-49-1
• 化学式: C₁₇H₁₄FN₇O
• 分子量: 351.343
• InChiKey: CLWJRULKTFGNLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-乙酰基胍 、 以 乙腈 为溶剂， 反应 1.0h， 生成 N-(5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(5-fluoro-6-methylpyridin-2-yl)-1H-imidazol-2-yl)acetamide
  参考文献：
  名称：

  2-Aminoimidazoles inhibitors of TGF-β receptor 1

  摘要：

  The 4-(5-fluoro-6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-ylamine 3 is a potent and selective inhibitor of TGF-betaR1. Substitution of the amino group of 3 typically led to a slight decrease in the affinity for the receptor and in TGF-beta-inducted PAI-luciferase reporter activity. However, 2-acetamidoimidazoles were identified as attractive candidates for further optimization as a result of their significant activity combined to their superior pharmacokinetic profile.

  DOI：

  10.1016/j.bmcl.2008.11.119

文献信息

• 2-Aminoimidazoles inhibitors of TGF-β receptor 1
  作者：Dominique Bonafoux、Claudio Chuaqui、P. Ann Boriack-Sjodin、Chris Fitch、Gretchen Hankins、Serene Josiah、Cheryl Black、Gregg Hetu、Leona Ling、Wen-Cherng Lee

  DOI：10.1016/j.bmcl.2008.11.119

  日期：2009.2

  The 4-(5-fluoro-6-methyl-pyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-ylamine 3 is a potent and selective inhibitor of TGF-betaR1. Substitution of the amino group of 3 typically led to a slight decrease in the affinity for the receptor and in TGF-beta-inducted PAI-luciferase reporter activity. However, 2-acetamidoimidazoles were identified as attractive candidates for further optimization as a result of their significant activity combined to their superior pharmacokinetic profile.